Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Clinical application of <sup>1</sup>H MRS in the human brain at 7T.

Frontiers in neuroscience·2026
Same author

Performance of traumatic encephalopathy syndrome criteria in identifying individuals with chronic traumatic encephalopathy.

Nature medicine·2026
Same author

Chronic traumatic encephalopathy neuropathologic change is associated with highest stage limbic-predominant age-related TDP-43 encephalopathy.

Journal of neuropathology and experimental neurology·2026
Same author

Neoantigens and stochastic fluctuations regulate T cell proliferation in primary and metastatic malignant brain tumours.

Journal of the Royal Society, Interface·2026
Same author

Depression is both a risk factor for and outcome from traumatic brain injury in UK Biobank (N = 502,356).

Journal of affective disorders·2026
Same author

Increased CD3 Immunoreactive Cells Persist Chronically in the Brain Parenchyma in Association with Focal Cortical Contusion following Experimental TBI.

bioRxiv : the preprint server for biology·2026

Related Experiment Video

Updated: May 31, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.5K

Enhanced Interleukin 6 Trans-Signaling Modulates Disease Process in Amyotrophic Lateral Sclerosis Mouse Models.

Carol Milligan1, Dale O Cowley2, William Stewart1

  • 1Department of Translational Neuroscience, Wake Forest University School of Medicine, Winston-Salem, NC 27157, USA.

Brain Sciences
|January 24, 2025
PubMed
Summary
This summary is machine-generated.

Enhanced IL6 trans-signaling accelerates Amyotrophic Lateral Sclerosis (ALS) progression in mice. Blocking IL6 receptor did not affect disease, suggesting targeted therapies are needed for ALS patients with the common IL6 receptor variant.

Keywords:
astrocytesglial cellsmicrogliamotoneuronsmotor neuron diseaseneuroimmuneneuromuscular junctions

More Related Videos

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.5K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.0K

Related Experiment Videos

Last Updated: May 31, 2025

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS
06:49

A Quick Phenotypic Neurological Scoring System for Evaluating Disease Progression in the SOD1-G93A Mouse Model of ALS

Published on: October 6, 2015

19.5K
Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis
08:59

Real-Time Fluorescent Measurement of Synaptic Functions in Models of Amyotrophic Lateral Sclerosis

Published on: July 16, 2021

2.5K
Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS
12:35

Clinical Testing and Spinal Cord Removal in a Mouse Model for Amyotrophic Lateral Sclerosis ALS

Published on: March 17, 2012

28.0K

Area of Science:

  • Neuroscience
  • Immunology
  • Genetics

Background:

  • Amyotrophic Lateral Sclerosis (ALS) mechanisms remain unclear despite extensive research.
  • Neurodegenerative diseases may share common toxic pathways.
  • IL6 trans-signaling is a potential therapeutic target for ALS.

Purpose of the Study:

  • To investigate the role of IL6 trans-signaling in ALS pathogenesis.
  • To determine if enhanced IL6 trans-signaling accelerates ALS progression.
  • To evaluate the efficacy of IL6 receptor blockade in an ALS mouse model.

Main Methods:

  • Developed mouse models with controlled IL6 trans-signaling.
  • Bred SOD1 transgenic mice with IL6R trans-signaling mice.
  • Assessed symptom onset, neuromuscular junction (NMJ) denervation, glial activation, and motoneuron (MN) survival.

Main Results:

  • Enhanced IL6 trans-signaling accelerated ALS symptom onset and pathological processes.
  • IL6 receptor blockade did not modify disease progression.
  • These findings suggest a role for IL6 trans-signaling in ALS disease modification.

Conclusions:

  • Enhanced IL6 trans-signaling exacerbates ALS pathology.
  • Targeted therapeutic strategies are required for ALS patients, particularly those with the IL6R Asp358Ala variant.
  • Further research into site-specific IL6 trans-signaling and drug bioavailability is necessary.